Pharmaceutical - Heptares Therapeutics

Filter

Current filters:

Heptares Therapeutics

Popular Filters

Heptares gets first research milestone from Cubist

22-07-2013

UK GPCR drug discovery and development company Heptares Therapeutics says it has achieved the first research…

Cubist PharmaceuticalsFinancialHeptares TherapeuticsPharmaceuticalResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Cubist partners with Heptares on new medicines targeting GPCRs; provides 2012 business update

08-01-2013

UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, has signed an…

ceftolozaneCubist PharmaceuticalsFinancialGenito-urinaryHeptares TherapeuticsLicensingPharmaceuticalResearchtazobactam

Shire signs $190 million deal for preclinical CNS drug

21-03-2012

Ireland-headquartered drugmaker Shire (LSE: SHP) has exercised its exclusive option to license a novel…

Heptares TherapeuticsLicensingNeurologicalPharmaceuticalShire

Back to top